The impact of pediatric labeling changes on prescribing patterns of cough and cold medications

Maryann Mazer-Amirshahi, Irit Rasooly, Gill Brooks, Jesse Pines, Larissa S May, John Van Den Anker

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective To evaluate the impact of initiatives created by the pharmaceutical industry and the Food and Drug Administration to limit the use of over-the-counter (OTC) cough and cold medications (CCMs) in young children in emergency departments (EDs) and ambulatory clinics.

Study design Analysis of the National Hospital Ambulatory Medical Care Survey and National Ambulatory Medical Care Survey was performed comparing 2005-2006 and 2009-2010 in children aged ≤12 years with a reason for visit consistent with cough or cold-related symptoms. Data were stratified by age (<2 years, 2-6 years, and 6-12 years). Descriptive frequencies and survey-weighted χ2 tests were used to assess OTC and prescription CCM prescription rates in ED and ambulatory clinic settings.

Results Comparing 2005-2006 and 2009-2010 revealed no changes in ED use of OTC CCMs; however, the use of prescription CCMs decreased, from 6.7% to 2.9% (P =.001). In ambulatory clinics, the overall rate of OTC CCM use increased from 6.3% to 11.1% (P =.001); however, use by children aged <2 years was unchanged. Prescription CCM use in EDs declined in all age groups, but in ambulatory clinics, decreases were significant only in patients aged <2 years.

Conclusion Implementation of pharmaceutical industry and Food and Drug Administration initiatives did not decrease the use of OTC CCMs in children aged <2 years in EDs or ambulatory clinics. The use of prescription CCMs was decreased in both settings, however. 2014 Elsevier Inc.

Original languageEnglish (US)
Pages (from-to)1024-1028.e1
JournalJournal of Pediatrics
Volume165
Issue number5
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Cough
Pediatrics
Prescriptions
Hospital Emergency Service
Health Care Surveys
Drug Industry
United States Food and Drug Administration
Age Groups

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The impact of pediatric labeling changes on prescribing patterns of cough and cold medications. / Mazer-Amirshahi, Maryann; Rasooly, Irit; Brooks, Gill; Pines, Jesse; May, Larissa S; Van Den Anker, John.

In: Journal of Pediatrics, Vol. 165, No. 5, 01.11.2014, p. 1024-1028.e1.

Research output: Contribution to journalArticle

Mazer-Amirshahi, M, Rasooly, I, Brooks, G, Pines, J, May, LS & Van Den Anker, J 2014, 'The impact of pediatric labeling changes on prescribing patterns of cough and cold medications', Journal of Pediatrics, vol. 165, no. 5, pp. 1024-1028.e1. https://doi.org/10.1016/j.jpeds.2014.07.047
Mazer-Amirshahi, Maryann ; Rasooly, Irit ; Brooks, Gill ; Pines, Jesse ; May, Larissa S ; Van Den Anker, John. / The impact of pediatric labeling changes on prescribing patterns of cough and cold medications. In: Journal of Pediatrics. 2014 ; Vol. 165, No. 5. pp. 1024-1028.e1.
@article{1a6fa624453b4902ae8473e4de34f92d,
title = "The impact of pediatric labeling changes on prescribing patterns of cough and cold medications",
abstract = "Objective To evaluate the impact of initiatives created by the pharmaceutical industry and the Food and Drug Administration to limit the use of over-the-counter (OTC) cough and cold medications (CCMs) in young children in emergency departments (EDs) and ambulatory clinics.Study design Analysis of the National Hospital Ambulatory Medical Care Survey and National Ambulatory Medical Care Survey was performed comparing 2005-2006 and 2009-2010 in children aged ≤12 years with a reason for visit consistent with cough or cold-related symptoms. Data were stratified by age (<2 years, 2-6 years, and 6-12 years). Descriptive frequencies and survey-weighted χ2 tests were used to assess OTC and prescription CCM prescription rates in ED and ambulatory clinic settings.Results Comparing 2005-2006 and 2009-2010 revealed no changes in ED use of OTC CCMs; however, the use of prescription CCMs decreased, from 6.7{\%} to 2.9{\%} (P =.001). In ambulatory clinics, the overall rate of OTC CCM use increased from 6.3{\%} to 11.1{\%} (P =.001); however, use by children aged <2 years was unchanged. Prescription CCM use in EDs declined in all age groups, but in ambulatory clinics, decreases were significant only in patients aged <2 years.Conclusion Implementation of pharmaceutical industry and Food and Drug Administration initiatives did not decrease the use of OTC CCMs in children aged <2 years in EDs or ambulatory clinics. The use of prescription CCMs was decreased in both settings, however. 2014 Elsevier Inc.",
author = "Maryann Mazer-Amirshahi and Irit Rasooly and Gill Brooks and Jesse Pines and May, {Larissa S} and {Van Den Anker}, John",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.jpeds.2014.07.047",
language = "English (US)",
volume = "165",
pages = "1024--1028.e1",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - The impact of pediatric labeling changes on prescribing patterns of cough and cold medications

AU - Mazer-Amirshahi, Maryann

AU - Rasooly, Irit

AU - Brooks, Gill

AU - Pines, Jesse

AU - May, Larissa S

AU - Van Den Anker, John

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objective To evaluate the impact of initiatives created by the pharmaceutical industry and the Food and Drug Administration to limit the use of over-the-counter (OTC) cough and cold medications (CCMs) in young children in emergency departments (EDs) and ambulatory clinics.Study design Analysis of the National Hospital Ambulatory Medical Care Survey and National Ambulatory Medical Care Survey was performed comparing 2005-2006 and 2009-2010 in children aged ≤12 years with a reason for visit consistent with cough or cold-related symptoms. Data were stratified by age (<2 years, 2-6 years, and 6-12 years). Descriptive frequencies and survey-weighted χ2 tests were used to assess OTC and prescription CCM prescription rates in ED and ambulatory clinic settings.Results Comparing 2005-2006 and 2009-2010 revealed no changes in ED use of OTC CCMs; however, the use of prescription CCMs decreased, from 6.7% to 2.9% (P =.001). In ambulatory clinics, the overall rate of OTC CCM use increased from 6.3% to 11.1% (P =.001); however, use by children aged <2 years was unchanged. Prescription CCM use in EDs declined in all age groups, but in ambulatory clinics, decreases were significant only in patients aged <2 years.Conclusion Implementation of pharmaceutical industry and Food and Drug Administration initiatives did not decrease the use of OTC CCMs in children aged <2 years in EDs or ambulatory clinics. The use of prescription CCMs was decreased in both settings, however. 2014 Elsevier Inc.

AB - Objective To evaluate the impact of initiatives created by the pharmaceutical industry and the Food and Drug Administration to limit the use of over-the-counter (OTC) cough and cold medications (CCMs) in young children in emergency departments (EDs) and ambulatory clinics.Study design Analysis of the National Hospital Ambulatory Medical Care Survey and National Ambulatory Medical Care Survey was performed comparing 2005-2006 and 2009-2010 in children aged ≤12 years with a reason for visit consistent with cough or cold-related symptoms. Data were stratified by age (<2 years, 2-6 years, and 6-12 years). Descriptive frequencies and survey-weighted χ2 tests were used to assess OTC and prescription CCM prescription rates in ED and ambulatory clinic settings.Results Comparing 2005-2006 and 2009-2010 revealed no changes in ED use of OTC CCMs; however, the use of prescription CCMs decreased, from 6.7% to 2.9% (P =.001). In ambulatory clinics, the overall rate of OTC CCM use increased from 6.3% to 11.1% (P =.001); however, use by children aged <2 years was unchanged. Prescription CCM use in EDs declined in all age groups, but in ambulatory clinics, decreases were significant only in patients aged <2 years.Conclusion Implementation of pharmaceutical industry and Food and Drug Administration initiatives did not decrease the use of OTC CCMs in children aged <2 years in EDs or ambulatory clinics. The use of prescription CCMs was decreased in both settings, however. 2014 Elsevier Inc.

UR - http://www.scopus.com/inward/record.url?scp=84908284890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908284890&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2014.07.047

DO - 10.1016/j.jpeds.2014.07.047

M3 - Article

C2 - 25195159

AN - SCOPUS:84908284890

VL - 165

SP - 1024-1028.e1

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 5

ER -